DWI cerebellar infarct volume as predictor of outcomes after endovascular treatment of acute basilar artery occlusion.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 27 08 2020
revised: 27 10 2020
accepted: 06 11 2020
pubmed: 28 11 2020
medline: 21 10 2021
entrez: 27 11 2020
Statut: ppublish

Résumé

Preprocedural predictors of outcome in patients with acute basilar artery occlusion (ABAO) who have undergone endovascular treatment (EVT) remain controversial. Our aim was to determine if pre-EVT diffusion-weighted imaging cerebellar infarct volume (CIV) is a predictor of 90-day outcomes. We analyzed consecutive MRI-selected endovascularly treated patients with ABAO within the first 24 hours after symptom onset. Successful reperfusion was defined as a modified Thrombolysis in Cerebral Infarction score of 2b-3. Using the initial MRI, baseline CIV was calculated in mL on an apparent diffusion coefficient map reconstruction (Olea Sphere software). CIV was analyzed in univariate and multivariable models as a predictor of 90-day functional independence (modified Rankin Scale (mRS) 0-2) and mortality. According to receiver operating characteristic (ROC) analysis, the optimal cut-off was determined by maximizing the Youden index to evaluate the prognostic value of CIV. Of the 110 MRI-selected patients with ABAO, 64 (58.18%) had a cerebellar infarct. The median CIV was 9.6 mL (IQR 2.7-31.4). Successful reperfusion was achieved in 81.8% of the cases. At 90 days the proportion of patients with mRS ≤2 was 31.8% and the overall mortality rate was 40.9%. Baseline CIV was significantly associated with 90-day mRS 0-2 (p=0.008) in the univariate analysis and was an independent predictor of 90-day mortality (adjusted OR 1.79, 95% CI 1.25 to 2.54, p=0.001). The ROC analysis showed that a CIV ≥4.7 mL at the initial MRI was the optimal cut-off to discriminate patients with a higher risk of death at 90 days (area under the ROC curve (AUC)=0.74, 95% CI 0.61 to 0.87, sensitivity and specificity of 87.9% and 58.1%, respectively). In our series of MRI-selected patients with ABAO, pre-EVT CIV was an independent predictor of 90-day mortality. The risk of death was increased for baseline CIV ≥4.7 mL.

Sections du résumé

BACKGROUND BACKGROUND
Preprocedural predictors of outcome in patients with acute basilar artery occlusion (ABAO) who have undergone endovascular treatment (EVT) remain controversial. Our aim was to determine if pre-EVT diffusion-weighted imaging cerebellar infarct volume (CIV) is a predictor of 90-day outcomes.
METHODS METHODS
We analyzed consecutive MRI-selected endovascularly treated patients with ABAO within the first 24 hours after symptom onset. Successful reperfusion was defined as a modified Thrombolysis in Cerebral Infarction score of 2b-3. Using the initial MRI, baseline CIV was calculated in mL on an apparent diffusion coefficient map reconstruction (Olea Sphere software). CIV was analyzed in univariate and multivariable models as a predictor of 90-day functional independence (modified Rankin Scale (mRS) 0-2) and mortality. According to receiver operating characteristic (ROC) analysis, the optimal cut-off was determined by maximizing the Youden index to evaluate the prognostic value of CIV.
RESULTS RESULTS
Of the 110 MRI-selected patients with ABAO, 64 (58.18%) had a cerebellar infarct. The median CIV was 9.6 mL (IQR 2.7-31.4). Successful reperfusion was achieved in 81.8% of the cases. At 90 days the proportion of patients with mRS ≤2 was 31.8% and the overall mortality rate was 40.9%. Baseline CIV was significantly associated with 90-day mRS 0-2 (p=0.008) in the univariate analysis and was an independent predictor of 90-day mortality (adjusted OR 1.79, 95% CI 1.25 to 2.54, p=0.001). The ROC analysis showed that a CIV ≥4.7 mL at the initial MRI was the optimal cut-off to discriminate patients with a higher risk of death at 90 days (area under the ROC curve (AUC)=0.74, 95% CI 0.61 to 0.87, sensitivity and specificity of 87.9% and 58.1%, respectively).
CONCLUSIONS CONCLUSIONS
In our series of MRI-selected patients with ABAO, pre-EVT CIV was an independent predictor of 90-day mortality. The risk of death was increased for baseline CIV ≥4.7 mL.

Identifiants

pubmed: 33243771
pii: neurintsurg-2020-016804
doi: 10.1136/neurintsurg-2020-016804
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

995-1001

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Isabelle Mourand (I)

Neurology, University Hospital Centre Montpellier, Montpellier, Languedoc-Roussillon, France i-mourand@chu-montpellier.fr.

Mehdi Mahmoudi (M)

Neuroradiology, University Hospital Center Montpellier, Montpellier, Languedoc-Roussillon, France.

Cyril Dargazanli (C)

Neuroradiology, University Hospital Center Montpellier, Montpellier, Languedoc-Roussillon, France.

Frederique Pavillard (F)

Reanimation, University Hospital Centre Montpellier, Montpellier, Languedoc-Roussillon, France.

Caroline Arquizan (C)

Neurology, University Hospital Centre Montpellier, Montpellier, Languedoc-Roussillon, France.

Julien Labreuche (J)

Biostatistics, University Hospital Center Lilles, Lilles, France.

Imad Derraz (I)

Neuroradiology, University Hospital Center Montpellier, Montpellier, Languedoc-Roussillon, France.

Nicolas Gaillard (N)

Neurology, University Hospital Centre Montpellier, Montpellier, Languedoc-Roussillon, France.

Genevieve Blanchet-Fourcade (G)

Neurology, Hospital Center Narbonne, Narbonne, Languedoc-Roussillon, France.

Pierre Henri Lefevre (PH)

Neuroradiology, University Hospital Center Montpellier, Montpellier, Languedoc-Roussillon, France.

Yassine Boukriche (Y)

Neurology, Hospital Center Beziers, Beziers, Languedoc-Roussillon, France.

Gregory Gascou (G)

Neuroradiology, University Hospital Center Montpellier, Montpellier, Languedoc-Roussillon, France.

Lucas Corti (L)

Neurology, University Hospital Centre Montpellier, Montpellier, Languedoc-Roussillon, France.

Vincent Costalat (V)

Neuroradiology, University Hospital Center Montpellier, Montpellier, Languedoc-Roussillon, France.

Emmanuelle Le Bars (E)

Neuroradiology, University Hospital Center Montpellier, Montpellier, Languedoc-Roussillon, France.

Federico Cagnazzo (F)

Neuroradiology, University Hospital Center Montpellier, Montpellier, Languedoc-Roussillon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH